Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Phase 2CompletedNCT00290914

Pharmacology Research Institute

Overview

The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients 18-65 years of age, inclusive.

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.